1 Replication origins
are 'licensed' for a single initiation event by loading
2 lent, inactivated influenza vaccine (TIV-HD)
was licensed for adults aged >/=65 years.
3 forms, many viral vector-based vaccines have
been licensed for animals.
4 of endotoxin priming, the NLRP3 inflammasome
is licensed for ATP-induced release of processed IL-18,
5 tic vaccine from one manufacturer having now
been licensed for commercial use and the expectation tha
6 d-generation tyrosine kinase inhibitors have
been licensed for first-line use.
7 s vaccines, Rotarix (RV1) and RotaTeq (RV5),
were licensed for global use in 2006.
8 OCVs have
been licensed for &
gt;20 years, but their potential for pre
9 New vaccines have
been licensed for hepatitis A, varicella, and typhoid.
10 iruses for which no vaccines or therapeutics
are licensed for human use.
11 e, only a few adjuvants and delivery systems
are licensed for human use.
12 ree (abciximab, eptifibatide, and tirofiban)
are licensed for human use.
13 ) have been shown to be efficacious and have
been licensed for human use, the surface glycoproteins h
14 ine efficacy has been reported and none have
been licensed for human use.
15 MF59-adjuvanted influenza vaccines
were licensed for human vaccination, but the detailed me
16 Zoster vaccine
is licensed for persons aged 50 years or older, but its
17 PDE5 inhibitors (eg, sildenafil)
are licensed for PH, but a role for PDE2 in lung physiol
18 children, and a live, oral vaccine may soon
be licensed for prevention.
19 Multiple biologic treatments
are licensed for psoriasis.
20 in genome stability in eukaryotic cells, DNA
is licensed for replication only after the cell has comp
21 the H. influenzae type b conjugate vaccines
were licensed for routine immunization of infants.
22 te mitosis and early G1, replication origins
are licensed for subsequent replication by loading heter
23 te mitosis and early G1, replication origins
are licensed for subsequent use by loading complexes of
24 es widely used within PICUs neither of which
being licensed for that use.
25 tazone, are insulin sensitizing agents, that
are licensed for the management of hyperglycaemia.
26 fumarate (TDF) and adefovir dipivoxil (ADV)
are licensed for the treatment of HIV-1 and HBV infectio
27 blockade with abatacept (CTLA4-Ig) will soon
be licensed for the treatment of rheumatoid arthritis -
28 Several novel therapies have
been licensed for the treatment of myeloma in recent yea
29 diterpenoids include ingenol mebutate, which
is licensed for the treatment of a precancerous skin con
30 Infliximab
is licensed for the treatment of Crohn's disease (CD) an
31 Etanercept
is licensed for the treatment of RA, including juvenile
32 e ligand of Toll-like receptor-7 (TLR7) that
is licensed for the treatment of viral infections and ca
33 , including juvenile RA, and, more recently,
was licensed for the treatment of psoriatic arthritis.
34 ts were newly licensed registered nurses who
were licensed for the first time between August 1st, 200
35 Omalizumab
is licensed for therapy in severe allergic asthma with a
36 ivated protein C (rhAPC [Xigris; Eli Lilly])
is licensed for treating human patients with severe seps
37 dditional analog, Pomalidomide, has recently
been licensed for treatment of multiple myeloma, and is
38 These analogues
are licensed for type 2 diabetes, but their efficacy in
39 Two rotavirus vaccines have recently
been licensed for use in >80 countries worldwide but not
40 clinical trial and a similar DNA vaccine has
been licensed for use in horses.
41 o herpes simplex virus 2 (HSV-2) vaccine has
been licensed for use in humans.
42 A vaccine (4CMenB) has now
been licensed for use in the European Union, comprising
43 on-based prognostic breast cancer tests have
been licensed for use.
44 ce 1969, several rubella virus vaccines have
been licensed for use; however, until the 1990s, use of
45 ials in lupus nephritis, no second line drug
is licensed for use in induction of remission in lupus n
46 ive agent of Argentine hemorrhagic fever, it
is licensed for use only in areas where Argentine hemorr
47 occal conjugated polysaccharide vaccine PC7V
was licensed for use among children in 2000.
48 drivalent human papillomavirus (HPV) vaccine
was licensed for use in 9- through 26-year-old females i
49 p A meningococcal conjugate vaccine (PsA-TT)
was licensed for use in sub-Saharan Africa in 2009.
50 otype-specific disease before and after PCV7
was licensed for use.